THE NASH MARKET (part 4 - Failures) 


EXPLORING THE IMPACT OF ONE DRUG PROGRAM CANCELLATION ON THE MARKET FORECASTS !

We explored the incidence of a trial failure inducing removal of drug from the potential market.

Click on the name of the drug removed from the market to see the impacts on the forecasts, you can zoom, clicking on the graphs.



None
Elafibranor (GENFIT)
OCA (INTERCEPT)
Cenicriviroc (ALLERGAN)
Emricasan (CONATUS)
GS4997 (GILEAD)
GR-MD-02 (GALECTIN)
Aramchol (GALMED)
MSDC-0602 (OCTETA)
Volixibat (SHIRE)
GS9674 (GILEAD)
IVA337 (INVENTIVA)
IMM124E (IMMURON)
Saroglitazar (ZYDUS)
GS0976 (GILEAD)
BMS 986038 (BMS)






Share on StockTwits

WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016